- Shionogi’s forecasted operating income for the fiscal year is 160.00 billion yen, which is higher than the estimated 146.01 billion yen.
- The projected net income is 163.00 billion yen, exceeding the predicted 150.13 billion yen.
- Net sales are foreseen to reach 455.00 billion yen, outdoing the estimate of 420.2 billion yen.
- The estimated dividend of 170.00 yen is greater than the previously predicted 156.91 yen.
- For the first half, Shionogi foresees net sales of 210.00 billion yen, operating income of 69.00 billion yen, and net income of 66.50 billion yen.
- Fourth quarter results show an operating income of 14.57 billion yen, contrasted to last year’s 2.53 billion yen, albeit lower than the estimate of 19.7 billion yen.
- The net income in the fourth quarter was 34.81 billion yen, a 28% increase year on year, which is marginally lower than the estimated 34.93 billion yen.
- Net sales in the fourth quarter were 98.26 billion yen, an 11% rise year on year, however lower than the estimated 105.91 billion yen.
- The operating income for the year was 153.31 billion yen, a 2.9% increase year on year, but slightly less than the estimate of 160.33 billion yen.
- Net income for the year was 162.03 billion yen, a 12% decrease year on year, yet marginally higher than the estimated 161.41 billion yen.
- Total net sales for the year were 435.08 billion yen, a 2% increase year on year, which is lower than the estimated 444.53 billion yen.
- The expertise on Shionogi’s stocks is divided with 9 suggesting to buy, 6 choosing to hold, and 1 recommending to sell.
A look at Shionogi & Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shionogi & Company Ltd., a pharmaceutical company known for developing prescription and over-the-counter drugs and diagnostics, presents a promising long-term outlook according to the Smartkarma Smart Scores. With solid scores across various key factors, including Value, Dividend, and Growth all at a score of 3, Shionogi & Co demonstrates a balanced performance in these areas. Furthermore, the company exhibits strong Resilience and Momentum with scores of 4, indicating its ability to weather uncertainties and maintain positive market trends.
Overall, the combination of these scores reflects a positive outlook for Shionogi & Co in the long run. Investors can be encouraged by the company’s consistent performance across key metrics, suggesting a stable foundation for continued growth and potential opportunities for value creation within the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
